Novartis Coartem Review Extends Past Deadline; Priority Review Voucher At Stake
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis is optimistic about prospects for near-term FDA approval of malaria drug.
You may also be interested in...
Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program
The process for "cashing in" a priority review voucher needs further clarification, three big pharma companies agree
Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program
The process for "cashing in" a priority review voucher needs further clarification, three big pharma companies agree
Committee Backs Novartis’ Coartem; May Be First Drug To Earn Priority Review Voucher
Anti-infective advisory committee overwhelmingly approves Coartem’s efficacy and safety, but with a laundry list of post-marketing study and labeling recommendations.